Nintedanib Plus Standard of Care Immunosuppression Versus Standard of Care Immunosuppression Alone in Patients With Progressive Fibrotic Myositis Associated - Interstitial Lung Disease: A Randomized, Double-Blind, Exploratory Trial
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 49
- 试验地点
- 10
- 主要终点
- Change in Living with Pulmonary Fibrosis Symptoms and Impact Questionnaire (L-PF) Dyspnea score
研究概览
简要总结
This research study will evaluate safety and how well the study drug, nintedanib improve symptoms in participants with myositis associated interstitial lung disease (MA-ILD). Interstitial lung disease is a disorder caused by the abnormal accumulation of cells structures between air sacs of the lungs resulting in thickening, stiffness and scarring of the tissues of the lung.
This study will enroll a total of 134 participants across 15 clinical sites located in the United States. A subset of participants will be enrolled remotely via telemedicine utilizing certified mobile home research nurses and various remote monitoring devices.
The research visits may include a physical exam, vital signs (such as blood pressure, heart rate, etc.), pulmonary function tests (PFT and/or home spirometry), Computerized Tomography (or CT) scans of the chest, blood draws, wearing a physical activity monitor and completing questionnaires. Some of these events may be done at home, at a local facility or remotely (via telemedicine).
详细描述
Participants enrolled in the study will receive either study drug or placebo for 12 weeks plus the participant's normal standard of care medication for the participant's disease. Placebo is an inactive substance that contains no medicine. Following the initial treatment phase, participants will receive the active study drug (nintedanib) for an additional 12-week period.
Nintedanib is a drug that is currently used and has been approved by the Food and Drug Administration (FDA) for the treatment of idiopathic pulmonary fibrosis (IPF), and has been shown to slow the rate of decline in pulmonary function among patients with IPF as well as interstitial lung disease (ILD) associated with systemic sclerosis or scleroderma. In addition, in March 2020, the FDA approved nintedanib oral capsules to treat patients with chronic fibrosing (scarring) interstitial lung diseases (ILD) with a progressive phenotype (trait).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
盲法说明
Subjects, investigators, and everyone involved in trial conduct or analysis or with any other interest in this double-blind trial will remain blinded with regard to the randomized treatment assignments until after the database lock.
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject has provided written informed consent
- •Approval from local treating physician (done at pre-screening only for remote patients as well as for local site patients not actively being managed at the local site).
- •Subject lives in the United States
- •Adult: Age ≥ 18 years
- •Subject can speak, read, and understand English or Spanish
- •Subject is willing and capable of performing all study procedures.
- •Validity/repeatability of home spirometry confirmed by PFT lab technician/MD through telemedicine as per American Thoracic Society guidelines.
- •Men and women of reproductive potential must agree to use 2 reliable methods of birth control during the trial period.
- •Clinical diagnosis of myositis or presence of one of the following myositis-specific or -associated autoantibodies).
- •Anti-synthetase autoantibody (Anti-Jo-1, -PL-7, -PL-12, -EJ, -OJ, -KS, -Tyr, -Zo)
- •Anti-MDA5, TIF1-gamma, Mi-2, NXP2/MJ, SAE, HMGCR, SRP
- •Anti-PM/Scl, Ku, U1RNP, Ro5,2/60, or SSA (in absence of clinical diagnosis of systemic sclerosis or primary Sjogren syndrome).
- •Fibrosing Interstitial Lung Disease (ILD):
- •HRCT chest within 12 months of screening visit with fibrosing ILD (reticular changes, traction bronchiectasis, and/or honeycombing)
- •No other identifiable cause of fibrosis
- •The following co-existing features are expected and accepted: ground glass opacity, upper lung or peri-bronchovascular predominance, mosaic attenuation, air trapping, consolidation, and centrilobular nodules.
- •Progressive ILD: Defined as meeting ≥1 of the following criteria within 24 months of the screening visit.
- •≥10% relative decline in FVC% predicted (%pred)
- •≥5 but <10% relative decline in FVC %pred with worsening dyspnea.
- •≥5 but <10% relative decline in FVC %pred with worsening chest HRCT fibrotic changes
- •Worsening dyspnea with worsening chest HRCT fibrosis
- •Worsening dyspenea with FCV% </= 70%
- •Standard of care (SOC) therapy: (See: SOC immunosuppression and washout under section 6.2 for details)
- •Allowable SOC includes a maximum of 2: 1 glucocorticoid (GC) and 1 Non-GC immunosuppressive medication (IS) Or 2 Non-GC immunosuppressive medications.
- •Allowable IS component of SOC regimen must have been started at least 12 weeks prior and be stable for at least 4 weeks before baseline visit.
- •In case a patient is not on any of the SOC immunosuppression, patient can be enrolled if at least 2 SOC immunosuppression are either previously failed or had intolerance or are contra-indicated.
- •Allowable GC component of SOC regimen must have been started at least 4 weeks prior and be stable for at least 2 weeks before baseline visit.
- •Allowable IS and GC:
- •Glucocorticoid (maximum dose ≤20 mg/day; prednisone equivalent). Mycophenolate mofetil (max dose 3 gm/day) Mycophenolic acid (max dose 2,160 mg/day) Azathioprine (max dose 2.5 mg/kg/day) Methotrexate (max dose 25 mg/week Tacrolimus (max dose 10 mg/day) Cyclosporine (max dose 200 mg/day) Leflunomide (max dose 20 mg/day) Sulfasalazine (max dose 3 gm/day) JAK inhibitors (tofacitinib max does 11 mg/day, upadacitinib max dose 15 mg/day, baricitinib max does 4 mg/day) IVIG (Intravenous immunoglobulin) or SQIG (subcutaneous immunoglobulin) (max dose 2 gm/kg/month) is allowed and not considered as SOC IS therapy Rituximab (maximum dose 1000 mg x 2 (2 weeks apart) or 375mg/m2 weekly dose x 4, repeated every > 4 months) Hydroxychloroquine is allowed and not considered as SOC IS therapy. Orencia (max dose of 125 mg SQ once a week or 1 gm monthly IV infusion)
- •Inhaled medication(s) for lung disease is allowed if started > 4 weeks before screening.
- •Should remain stable throughout the study.
- •Negative pregnancy test
排除标准
- •Planned major surgical procedures within the trial period of 24 weeks.
- •Women who are pregnant, nursing, or who plan to become pregnant while in the trial.
- •Women of childbearing potential* not willing or able to use at least two highly effective methods of birth control.
- •For females of reproductive potential: use of highly effective contraception for at least 1 month before study drug administration and agreement to use such a method during study participation and for an additional 28 days after the end of study drug administration.
- •For males of reproductive potential**: use of condoms or other methods to ensure effective contraception with a partner
- •Highly effective contraception examples are:
- •An approved hormonal contraceptive such as oral contraceptives, emergency contraception used as directed, patches, implants, injections, rings, hormonally-impregnated intrauterine device (IUD), or nonhormonal IUD.
- •Abstinence
- •A woman is considered of childbearing potential, i.e. fertile, following menarche, and until becoming post-menopausal unless permanently sterile. Permanent sterilization methods include hysterectomy, bilateral salpingectomy, tubal occlusion, and bilateral oophorectomy.
- •A man is considered permanently sterile if a vasectomy has been performed.
- •Severe lung disease is defined by the following within the last 6 months before the screening:
- •FVC ≤40 percent predicted
- •DLCO <30% of percent predicted (corrected for Hb)
- •O2 requirement of ≥10 L at rest based on home oxygen prescription.
- •Patient listed for lung transplant or actively going through lung transplant evaluation.
- •Moderate to severe active muscle disease from myositis as per any one of the criteria:
- •Creatine kinase (CK) > 2000 U/mL.
- •Moderate to severe dermatomyositis rashes as per investigator evaluation (if rash present)
- •Moderate to severe arthritis as per investigator evaluation
- •Moderate to severe muscle weakness as per Sit to Stand 30 seconds of <
- •History of or ongoing serious active, chronic, or recurrent infection within 4 weeks of screening
- •Significant Pulmonary Hypertension (PH) is defined by any of the following:
- •Current clinical diagnosis of moderate to severe PH or significant right heart failure.
- •History of echocardiographic evidence of significant right heart failure or moderate to severe PH (TR jet >= 2.9 m/s and signs of right ventricle (RV) dysfunction; or TR jet > 3.4; or an right ventricle systolic pressure (RVSP) > 40-55 with evidence of RV strain or dysfunction; or RVSP > 55 regardless.
- •History of right heart catheterization showing a cardiac index ≤ 2.2 l/min/m² or severity of pulmonary hypertension (mPAP) >40 millimeters of mercury (mmHg) with a pulmonary capillary wedge pressure (PCWP) <15mmHg
- •PH requiring oral, IV, or inhaled therapy (such as epoprostenol, treprostinil, iloprost, bosentan, ambrisentan, sildenafil, and tadalafil).
- •Increased bleeding risk, defined by any of the following:
- •Patients who require
- •Fibrinolysis, full-dose therapeutic anticoagulation (e.g. vitamin K antagonists, direct thrombin inhibitors, heparin, factor Xa inhibitors, low molecular weight heparin)
- •High dose antiplatelet therapy (>325mg acetylsalicylic acid or >75mg clopidogrel).
- •History of hemorrhagic central nervous system (CNS) event within 12 months of screening.
- •Any of the following within 3 months of screening:
- •Hemoptysis or hematuria
- •Active gastrointestinal (GI) bleeding or active GI ulcers.
- •Coagulation parameters: International normalized ratio (INR) >2, prolongation of prothrombin time (PT) and by >1.5 x ULN at screening.
- •History of a thrombotic event (including stroke and transient ischemic attack) within 12 months of screening.
- •Severe Cardiovascular disease, any of the following:
- •Severe hypertension, uncontrolled under treatment (≥160/100 mmHg), within 6 months of screening.
- •Myocardial infarction or unstable cardiac angina within 6 months of screening.
- •Patients with underlying chronic liver disease (Child-Pugh A, B, or C hepatic impairment).
- •Known hypersensitivity to the trial medication or its components (i.e. soya lecithin)
- •Other diseases that may interfere with testing procedures or in the judgment of the Investigator may interfere with trial participation (such as significant GI issues like irritable bowel syndrome, inflammatory bowel disease, recent abdominal surgery, diverticular disease), or significant other lung diseases (such as severe obstructive lung disease such as severe asthma or severe chronic obstructive pulmonary disease, etc.) or may put the patient at risk when participating in this trial.
- •Life expectancy for a disease other than ILD < 2.5 years (Investigator assessment).
- •In the opinion of the investigator, any condition precluding participation and completion of the study, including active alcohol and drug abuse or patients not able to understand or follow trial procedures.
- •Other investigational therapy was received within 1 month or 6 half-lives (whichever was greater) before the screening visit.
- •Current treatment with nintedanib or pirfenidone (taken the drug within 3 months of randomization or history of intolerance/side effects)
- •Current or recent use of one or more of the following medications (See: SOC immunosuppression and washout under section 6.2 for details)
- •Cyclophosphamide within 3 months of baseline.
- •Anti-tumor necrosis factor (infliximab, golimumab, or certolizumab) within 8 weeks or adalimumab within 4 weeks, and etanercept within 2 weeks of baseline.
- •Anakinra within 1 week of baseline.
- 另有 7 项未显示
研究组 & 干预措施
Placebo plus Standard of Care, then Nintedanib plus Standard of Care
Placebo twice a day (BID) plus standard of care (SOC) Immunosuppressive Therapy for 12 weeks followed by open-label Nintedanib 150 mg BID + SOC Immunosuppressive Therapy for additional 12 weeks.
干预措施: Nintedanib (Drug)
Placebo plus Standard of Care, then Nintedanib plus Standard of Care
Placebo twice a day (BID) plus standard of care (SOC) Immunosuppressive Therapy for 12 weeks followed by open-label Nintedanib 150 mg BID + SOC Immunosuppressive Therapy for additional 12 weeks.
干预措施: Placebo (Drug)
Placebo plus Standard of Care, then Nintedanib plus Standard of Care
Placebo twice a day (BID) plus standard of care (SOC) Immunosuppressive Therapy for 12 weeks followed by open-label Nintedanib 150 mg BID + SOC Immunosuppressive Therapy for additional 12 weeks.
干预措施: Standard of Care (Drug)
Nintedanib plus Standard of Care
Nintedanib 150 mg BID + SOC Immunosuppressive Therapy for 12 weeks followed by open-label Nintedanib 150mg BID + SOC Immunosuppressive Therapy for additional 12 weeks.
干预措施: Nintedanib (Drug)
Nintedanib plus Standard of Care
Nintedanib 150 mg BID + SOC Immunosuppressive Therapy for 12 weeks followed by open-label Nintedanib 150mg BID + SOC Immunosuppressive Therapy for additional 12 weeks.
干预措施: Standard of Care (Drug)
结局指标
主要结局
Change in Living with Pulmonary Fibrosis Symptoms and Impact Questionnaire (L-PF) Dyspnea score
时间窗: Baseline (week 0) to 12 weeks
The Living with Pulmonary Fibrosis (L-PF) questionnaire is a 44 item questionnaire with two modules: Symptoms (23 items) and Impacts (21 items). The Symptoms module yields three domain scores: 1) dyspnea, 2) cough and 3) fatigue as well as a total Symptoms score. The Impacts module yields a single Impacts score. Symptoms and Impacts scores are summed to yield a total L-PF score. Scoring is performed as a summary score, the mean of the dimension ratings multiplied by 100. Summary score range from 0-100, the higher the score the greater the impairment.
次要结局
- Proportion of patients with stable (+/- < 5%) or improved FVC (≥ 5, ≥ 7.5, ≥ 10%) (mL) from baseline to week 12(baseline (week 0) at week 12)
- Time to progression(Baseline (week 0) to week 24)
- Change in Living with Pulmonary Fibrosis Dyspnea score(Baseline (week 0) to week 24)
- Proportion of patients with a relative decline from baseline in FVC (mL) of ≥10%, ≥7.5%, and ≥ 5%(Weeks 12 and 24)
- Proportion of patients with stable (+/- < 5%) or improved FVC (≥ 5, ≥ 7.5, ≥ 10%) (mL) from baseline to week 24(baseline (week 0) at week 24)
- Time to FVC (mL) improvement and decline from baseline by (≥5%, 7.5%, 10%)(Baseline (week 0) to 24 weeks)
- Absolute and relative change in Forced Vital Capacity (FVC) (mL) from baseline to 12 weeks(Baseline (week 0) to week 12)
- Absolute and relative change in Forced Vital Capacity FVC (%) from baseline to week 12(Baseline (week 0) to week 12)
- Absolute and relative change in Forced Vital Capacity FVC (%) from baseline to week 24(Baseline (week 0) to week 24)
- Proportion of patients with stable (+/- < 5%) or improved FVC (≥ 5, ≥ 7.5, ≥ 10%) (%) from baseline to week 24(baseline (week 0) at week 24)
- Change in immunosuppressive (IS) regimen(Baseline (Week 0) to week 12)
- Absolute and relative change in Forced Vital Capacity (FVC) (mL) from baseline to 24 weeks(Baseline (week 0) to week 24)
- Change in other Living with Pulmonary Fibrosis scores(Week 12 to week 24)
- Proportion of patients with stable (+/- < 5%) or improved FVC (≥ 5, ≥ 7.5, ≥ 10%) (%) from baseline to week 12(baseline (week 0) at week 12)
- Proportion of patients with a relative decline from baseline in FVC (%) of ≥10%, ≥7.5%, and ≥ 5%(Weeks 12 and 24)
- Time to FVC (%) improvement and decline from baseline by (≥5%, 7.5%, 10%)(Baseline (week 0) to 24 weeks)
研究者
Rohit Aggarwal, MD
Professor of Medicine
University of Pittsburgh